Asta Medica, Aktiengesellschaft

Zentaris Ag

Baxter Healthcare Sa

Ziopharm Oncology, Inc.

Deutches Krebsforchunszentrum Stiftung Des Offentlichen Rechts

Thomas Klenner

Bernd Nickel

Thomas Beckers

Peter Hilgard

J&uuml;rgen Engel

Bernhard Kutscher

Peter Emig

Michael Bernd

Gerald Bacher

Erik Bruyneel

Kirsten Peters

Jurgen Engel

Horst Kessler

Dieter Sauerbier

Wolfgang Maier-Borst

Hans-Hermann Schrenk

Silke Baasner

Jürgen Engel

Werner Sarlikiotis

Juergen Engel

Eckhard Milsmann

Eckhard Friedrich

Georgi Graschew

Hans J Sinn

Dieter Wohrle

Erich G Roedern

Patricia-Marie Charpentier

Peter-Paul Emig

Sebastian Hose

Vichai Reutrakul

Juergen Schmidt

Gerhard Noessner

Thaiwatchai Santisuk

G&uuml;nter Kamp

Günter Kamp

The invention relates to the use of N-substituted indole-3-glyoxylamides of the general Formula I: and to pharmaceutical compositions having antitumor action.

Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties

The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.

Use of dopamine receptor antagonists in palliative tumor therapy

The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, antiemeticum, and/or an antidiarrhoeal.

Solid pharmaceutical compositions containing hexedecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis

This invention relates to novel xanthone compounds, their preparation and use as medicament. More particularly this invention is directed to the isolation of the novel xanthone natural product sootepenseone from Craib, Annonaceae, its identification and derivatization, and the use of sootepenseone and its derivatives as anticancer agents.

Xanthone compounds, their preparation and use as medicament

New LH-RH antagonists are disclosed, in particular peptidomimetics and peptides modified in a side chain, their salts with pharmaceutically acceptable acids and a process for preparing these LH-RH antagonists and their salts. The disclosed peptides represent analogues of the luteinising hormone releasing hormone (LH-RH). The disclosed compounds have a high antagonistic power and are free of undesirable side effects, in particular edematogenic effects.

LH-RH antagonists having improved action

The invention describes a novel method for determining the mass of vital tumor cells of xenotransplants in animal models. Cells altered by genetic engineering which form a tumor after transplantation synthesize an excreted reporter gene. This is shown by way of example for a secreted form of human placenta-specific, alkaline phosphate (SEAP). The latter can be demonstrated in the serum of test animals or in culture supernatants. The activity of SEAP in the serum correlates with the number of vital tumor cells in the animal and can be measured prior to the formation of a palpable tumor. The invention shows the use of cell lines altered by genetic engineering in such a manner in subcutaneous and orthotopic tumor models. Dicistronic, eukaryotic expression vectors are used for the stable transfection of the mammalian cell lines or tumor cells used. These vectors contain, under the control of a constitutive or inducible promotor element, the gene coding for SEAP, coupled with a second gene. This latter gene codes e.g. for a receptor tyrosine kinase such as erbB2/HER2 which transforms during overexpression.

Tumorigenic cell lines altered by genetic engineering and their use for

Tumor-active or tumor-diagnostic substances having preferred accumulation in the tumor, which are characterized in that they have

Polyether-substituted porphyrin anti-tumor agents

Use of 7-amino-L-glycero-L-gulo-2,6-anhydro-7-desoxy-heptonic acid and 2-benzoxycarbonylamino-0.sup.1 -methyl-2-desoxy-.beta.-glucopyranuronic acid, their derivatives and the enantiomorphous compounds for incorporation and for manufacture in pharmacologically active peptide hormones.

Use of D-glucopyranuronic acids and their derivatives for incorporation

Growing community of inventors

Ingelheim, Germany

Thomas Klenner